Tesamorelin/Ipamorelin 12/2MG
The TESA IPA peptide blend combines Tesamorelin and Ipamorelin, offering a dual approach to studying growth hormone release and its effects on metabolism, recovery, and cellular function in research applications.
-
Tesamorelin mimics GHRH to stimulate pituitary signaling
-
Ipamorelin activates ghrelin receptors for selective GH release
-
Blend supports studies on muscle growth, fat metabolism, and sleep regulation
$109.00
Availability: In stock
Tesamorelin + Ipamorelin (TESA IPA) Blend
The TESA IPA peptide blend combines Tesamorelin, a growth hormone–releasing hormone (GHRH) analog, with Ipamorelin, a selective growth hormone secretagogue. Together, they act through complementary pathways and enhance growth hormone activity in research settings.
For example, Tesamorelin supports pituitary signaling by mimicking natural GHRH. Meanwhile, Ipamorelin binds to ghrelin receptors to trigger GH release. It does so without raising cortisol or prolactin. Because of this, the dual action creates a stronger effect than either peptide alone.
In addition, researchers value the blend for studies on metabolic health, lean muscle growth, fat loss, and sleep quality. Moreover, research suggests this mix may help examine how growth hormone affects recovery, energy balance, and cognition.
Finally, TESA IPA is produced in precise, lab-grade formulations to support controlled testing. It is supplied only for research and development and is not intended for human use.
